Siemens Healthineers has signed an agreement with Netherlands-based imaging technology developer ScreenPoint Medical to jointly create artificial intelligence (AI)-based applications for breast imaging.
Under the collaborative deal, Siemens will also acquire a strategic minority stake in ScreenPoint.
The alliance will bring together Siemens’ breast imaging expertise and ScreenPoint’s experience in mammography decision support to devise clinical applications for the screening and diagnosis of the cancer.
Siemens Healthineers X-ray Products head Dr Peter Schardt said: “The aim of our collaboration with ScreenPoint Medical is to expand precision medicine by providing automated clinical decision support that makes it easier and faster to distinguish between healthy and tumour tissue, thus increasing diagnostic accuracy.
“Working with strong partners such as ScreenPoint will help us drive personalised breast care pathways with new applications based on deep learning and artificial intelligence.”
ScreenPoint’s portfolio includes mammography reading software called Transpara, which is designed to provide clinical decisions support and computer-aided detection to ensure high reading accuracy.
The software is said to have demonstrated the ability to aid radiologists in better identifying the cancer through mammography and can minimise variations between various users.
Transpara gained the European CE-Mark for use with Siemens’ digital mammography and reading portfolio, and ScreenPoint is planning to secure approvals for other clinical applications and countries.
ScreenPoint Medical CEO Nico Karssemeijer said: “Together with Siemens Healthineers, we can bring our expertise in AI into the entire screening and diagnostic pathway, starting from risk stratification to image acquisition and diagnosis.”
Siemens offers a variety of breast imaging solutions, including Mammomat Revelation that provides depth resolution with 50° wide angle for tomosynthesis, and Syngo.BreastCare designed for advanced 2D and 3D mammography visualisation.